STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER

596047 Disclosed herein is an orally deliverable pharmaceutical composition comprising a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier....

Full description

Saved in:
Bibliographic Details
Main Authors SANZGIRI, YESHWANT, FICKES, MICHAEL, HEEMSTRA, KATHERINE, FISCHER, CRISTINA, HAIGHT, ANTHONY R, SCHMITT, ERIC, ZHANG, GEOFF, TONG, PING, ZHOU, DELIANG, CATRON, NATHANIEL
Format Patent
LanguageEnglish
Published 29.11.2013
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:596047 Disclosed herein is an orally deliverable pharmaceutical composition comprising a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Bibliography:Application Number: NZ20100596047